Abstract
Men with testicular neoplasia (TN) and Hodgkin’s disease (HD) are those who more frequently require treatment for fertility because these malignancies affect patients during the reproductive age and because the early diagnosis and the improved anti-neoplastic treatments cure most of these patients. Although some of them can father a child spontaneously, assisted reproductive techniques allow fatherhood to patients with severe spermatogenesis impairment and this possibility has raised concern about the long-term consequence of the testicular damage induced by chemo- and/or radiotherapy. This paper reviews the effects of cancer per se and of anti-neoplastic treatments on gonadal function, sperm aneuploidy rate and sperm DNA integrity. A debate is still open as to whether TN or HD per se may impair spermatogenesis. Many studies have shown that this is the case, albeit others have challenged this view. Chemo- and/or radiotherapy affects negatively gonadal function, rendering almost all patients azoospermics. However, spontaneous pregnancies and a high degree of spermatogenesis recovery occur with time. A large body of literature on sperm chromosome complement suggests an increased rate of structural and numerical chromosome abnormalities in patients with cancer during anti-neoplastic treatment. A minority of them has, however, shown that this effect disappears with time. An interesting and relatively new aspect is the study of sperm DNA integrity in patients with TN and HD particularly following chemo- and/or radiotherapy. The scanty information available seems to suggest that these patients have a permanent or at least a long-lasting DNA fragmentation in their spermatozoa.
Similar content being viewed by others
References
Dahl O. Testicular carcinoma: a curable malignancy. Acta Radiol. Oncol. 1985, 24: 3–15.
Longo D., Young R., Wesley M., Hubbard S., Duffey P., Jaffe E., De Vita V.J. Twenty years of MOPP therapy for Hodgkin’s disease. J. Clin. Oncol. 1986, 4: 1295–1306.
Perreault S. Gamete toxicology: the impact of new technologies. In: Korach K. (Ed.), Reproduction and developmental toxicology. Marcel Dekker Inc., New York, 1998, pp. 635–641.
Petersen P.M., Skakkebaek N.E., Vistisen K., Rorth M., Giwercman A. Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J. Clin. Oncol. 1999, 17: 941–947.
Demkow T., Faundez R., Madej G. Sperm, LH FSH, testosterone evaluation in patients with testicular cancer. Preliminary study. Ginekol. Pol. 1998, 69: 405–409.
Nijman J.M., Schraffordt Koops H., Kremer J., Willemse P.H., Sleijfer D.T., Oldhoff J. Fertility and hormonal function in patients with a nonseminomatous tumor of the testis. Arch. Androl. 1985, 14: 239–246.
Petersen P.M., Skakkebaek N.E., M., Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J. Urol. 1999, 161: 822–826.
Carroll P.R., Whitmore W.F. Jr., Herr H.W., Morse M.J., Sogani P.C., Bajorunas D., Fair W.R., Chaganti R.S. Endocrine and exocrine profiles of men with testicular tumors before orchiectomy. J. Urol. 1987, 137: 420–423.
Gandini L., Lombardo F., Toselli L., Gilio B., Testani P., Anselmo A.P., Dondero F., Lenzi A. Sperm characteristics before and after therapy in patients with Hodgkin’s disease and testicular neoplasma. J. Endocrinol. Invest. 2000, 23 (Suppl. 8): 28, Abstract OC9.
Hendry W.F., Stedronska J., Jones C.R., Blackmore C.A., Barrett A., Peckham M.J. Semen analysis in testicular cancer and Hodgkin’s disease: pre- and post treatment findings and implications for cryopreservation. Br. J. Urol. 1983, 55: 769–773.
Stephenson W.T., Poirier S.M., Rubin L., Einhorn L.H. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J. Clin. Oncol. 1995, 13: 2278–2280.
Nijman J.M., Schraffordt Koops H., Kremer J., Sleijfer D.T. Gonadal function after surgery and chemotherapy in men with stage II and III nonseminomatous testicular tumors. J. Clin. Oncol. 1987, 5: 651–656.
Drasga R.E., Einhorn L.H., Williams S.D., Patel D.N., Stevens E.E. Fertility after chemotherapy for testicular cancer. J. Clin. Oncol. 1983, 1: 179–183.
Agarwal A., Tolentino M.V. Jr., Sidhu R.S., Ayzman I., Lee J.C., Thomas A.J. Jr., Shekarriz. M. Effects of cryopreservation on semen quality in patients with testicular cancer. Urology 1995, 46: 382–389.
Padron O.F., Sharma R.K., Thomas A.J. Jr., Agarwal A. Effects of cancer on spermatozoa quality after cryopreservation: a 12-year experience. Fertil. Steril. 1997, 67: 326–331.
Vigersky R.A., Chapman R.M., Berenberg A.R. Testicular dysfunction in untreated Hodgkin’s disease. Am. J. Med. 1982, 73: 482–486.
Viviani S., Ragni G., Santoro A., Perotti L., Caccamo E., Negretti E., Valagussa P., Bonadonna G. Testicular dysfunction in Hodgkin’s disease before and after treatment. Eur. J. Cancer 1991, 27: 1389–1392.
Chapman R.M., Sutcliffe S.B., Malpas J.S. Male gonadal dysfuction in Hodgkin’s disease: a prospective study. J. Am. Med. Assoc. 1981, 245: 1323–1328.
Kulkarni S.S., Satry P.S., Siakia T.K., Parish P.M., Gopal R., Advani S.H. Gonadal function following ABVD therapy for Hodgkin’s disease. Am. J. Clin. Oncol. 1997, 20: 354–357.
Gerres L., Brawswig J.H., Schelgel W., Jurgens H., Schellong G. The effects of etoposide on testicular function in boys treated for Hodgkin’s disease. Cancer 1998, 83: 2217–2222.
Heikens J., Berehndt H., Adriaanse R., Berghout A. Irreversible gonadal damage in male survivors of pedriatic Hodgkin’s disease. Cancer 1996, 78: 2020–2024.
De Braekeleer M., Dao T. Cytogenetic studies in males infertility: a review. Hum. Reprod. 1991, 6: 245–250
Alvarez R., Tusell L., Genescà R., Garcia-del-Muro X., Egozcue J. Absence of chromosomal instability in spermatozoa of men affected by testicular cancer. Hum. Reprod. 1999, 14: 247–251.
Templado C., Benet J., Genescà A., Navarro J., Caballin MR., Mirò R., Egozcue J. Human sperm chromosomes. Hum. Reprod. 1988, 3: 133–138.
Jenderny J., Rohborn G. Chromosome analysis of human sperm. I. First results with a modified method. Hum. Genet. 1987, 76: 385–388.
Genescà A., Mirò R., Caballin M.R., Benet J., Germa J.R., Egozcue S. Sperm chromosome studies in individuals treated for testicular cancer. Hum. Reprod. 1990, 5: 286–290.
Jenderny J., Jacobi M., Ruger A., Rohrborn G. Chromosome aberration in 450 sperm complements from eight controls and lack of increase after chemotherapy in two patients. Hum. Genet. 1992, 90: 151–154.
Martin R.H., Ernst S., Rademaker A., Barclay L., Ko E., Summers N. Chromosomal abnormlities in sperm from testicular cancer patients before and after chemotherapy. Hum. Genet. 1997, 99: 214–218.
Martin R. Human sperm chromosome complements in chemotherapy patients and infertile men. Chromosoma 1998, 107: 523–527.
Brandriff B.F., Meistrich M.L., Gordon L.A., Carrano A.V., Liang J.C. Chromosomal damage in sperm of patients surviving Hodgkin’s disease following MOPP (nitrogen mustard, vincritine, procarbazine, and prednisone) therapy with and without radiotherapy. Hum. Genet. 1994, 93: 295–299.
Robbins W.A., Marvin M.L., Moore D., Hagermeister F.B., Weier H.U., Cassel M.J., Wilson G., Eskenazi B., Wyrobeck A.J. Chemotherapy induces transient sex chromosomal and autosomal aneuploidy in human sperm. Nat. Genet. 1997, 16: 74–78.
Rousseaux S., Sèle B., Cozzi J., Chevret E. Immediate rearrangements of human sperm chromosomes following in vivo irradiation. Hum. Reprod. 1993, 8: 903–907.
Monteil M., Rousseaux S., Chevret E., Pelletier R., Cozzi J., Sele B. Increased aneuploid frequency in spermatozoa from a Hodgkin’s disease patient after chemotherapy and radiotherapy. Cytogenet. Cell Genet. 1997, 76: 134–138.
Gandini L., Lombardo F., Paoli D., Caponecchia L., Familiari G., Verlenga C., Dondero F., Lenzi A. Study of apoptotic DNA fragmentation in human spermatozoa. Hum. Reprod. 2000, 15: 830–839.
Evenson D.P., Klein F.A., Whitmore W.F., Melamed M.R. Flow cytometry evaluation of sperm from patients with testicular carcinoma. J. Urol. 1984, 132: 1220–1225.
Chatterjee R., Haines G.A., Perera D.M.D., Goldstone A., Morris I.D. Testicular and sperm DNA damnage after treatment with fludarabine for chronic lymphocytic leukaemia. Hum. Reprod. 2000, 15: 762–766.
Morris I.D., Hoyes K.P., Taylor M.F., Woolveridge I. Male reproductive toxicology. A review with special consideration to hazards to men. In: Hamamah S., Mieusset R. (Eds.), Male gametes: production and quality. INSERM, Paris, 1996, pp. 135–150.
Haines G., Marples B., Daniel P., Morris I. DNA damage in human and mouse spermatozoa after in vitro irradiation assessed by the comet assay. Adv. Exp. Med. Biol. 1998, 444: 79–93.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
De Palma, A., Vicari, E., Palermo, I. et al. Effects of cancer and anti-neoplastic treatment on the human testicular function. J Endocrinol Invest 23, 690–696 (2000). https://doi.org/10.1007/BF03343795
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343795